VEGFA and choroidal neovascularization: As an example, both the ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD) [6] and MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD) [7] trials revealed that ~10% of patients have a significant loss of visual acuity in the first 24 months of treatment after baseline.